The company said that there were three treatment-related serious adverse events reported with HLP003 in a late-stage trial, though it met its main goal.
The company said that there were three treatment-related serious adverse events reported with HLP003 in a late-stage trial, though it met its main goal.
Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.
Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.
The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.
Enveric stated during after-market hours on Thursday that it has entered into definitive agreements for the purchase and sale of 2.2 million shares of its common stock at a purchase price of $2.25.